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1. CARDIOVASCULAR DISEASE 
 
Cardiovascular disease, including coronary artery and peripheral vascular disease, is the 
leading cause of morbidity and mortality in word population. Peripheral arterial disease 
results in the manifestation of many serious conditions, including critical limb ischemia 
(CLI). CLI is the end-stage of lower extremity PAD in which severe obstruction of 
blood flow results in ischemic rest pain, ulcers and a significant risk for limb loss 
(Fig.1). 
 
 
 
FIG.1 Peripheral Artery Disease (PAD). Anatomic location (A); Peripheral Vascular Disease 
diagram.  
 
 
The clinical aim is the revascularization of occluded vessels to permit a functional 
reestablishment of blood flow. If not revascularized, patients with CLI can lose limbs or 
acquire other potentially fatal complications due to gangrene progression or sepsis. 
Common approaches and therapies used to treat PAD include changes in life style, 
drugs, or bypass surgery. 
A bypass surgery involves implantation of infrainguinal bypass to replace the diseased 
segment and to redirect blood flow around the blocked portion of the artery (Fig.2). 
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FIG.2 Replacement of diseased vessel 
 
 
There are three main classifications for a biological bypass graft: autografts, allograft, 
xenograft.  
 
Autografts utilize ones own vessels such as saphenous veins, mammary arteries and 
radial arteries. The chance of an immune response is low since the graft is from the 
host’s body. Unfortunately this approach requires multiple surgical procedures and is 
often limited by the quality and availability of autologous vein (Mirelli M. et al, 2005).  
In most cases the patient suffers from a number of pre-existing cardiovascular diseases 
and therefore may have atherosclerotic build up rendering any possible autologous 
vessels non-viable for grafting. 
 
Allograft, the vessel is donated from an individual of the same species. The institution 
of Cardiovascular Tissues Bank opened new frontiers in cardiovascular surgery, since it 
offers the possibility to have a large availability of cryopreserved allograft from 
multiorgan donors with different calibre and length to be used whether autologous 
material is not available or not adequate. 
However, the use of cryopreserved allograft is often unsatisfactory. The major 
disadvantage seems the immunological reaction caused from the persistence of cells 
components. The immunological reaction contributes to the degradation dilatation end 
consequent rupture of the graft (Chiesa R. et al, 2002). 
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Xenografts are synthetic vascular prosthesis that can be scaled up for high-throughput 
clinical uses. These types of graft are commonly used in peripheral bypass procedures 
for the implantation of large diameter graft, since they act as good conduits in high-flow 
low-resistance conditions (Bosma J. et al, 2012).  
For years synthetic graft have been made of poly(ethylene terphalates) [Dacron™] and 
expanded poly(tetrafluoroethylene) [ePTFE Teflon™]. Both of these materials have 
been used clinically for peripheral applications and have become well characterized and 
clinically tested with successful outcomes for large diameter (>6 mm) vessels (Peck M. 
et al, 2012). 
In the contrary, almost all vascular conduits with a smaller diameter (<6mm) fail in 5 
years, because of intimal hyperplasia, the increase of the number of the cells that form 
the inner layer of vessels, or atherosclerotic degeneration, plaque formation in the inner 
surface, thrombosis and consequent complications such as stenosis, sclerosis and vessel 
obstruction (Teebken OE. et al, 2002). 
To summarize, the use of either a synthetic or natural graft has specific individual 
limitations resulting in a high demand for alternative treatments (Table 1). 
 
 
 
Table1. Characteristics of vascular replacement methods 
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1.1 Cardiovascular System 
 
The circulatory system in adult human is a closed system characterized by a double and 
complete circulation.  It is composed of the heart and blood vessels, including arteries, 
veins, and capillaries (Fig.3). The heart is the key organ in the circulatory system. As a 
hollow, muscular pump, its main function is to propel blood throughout the body. 
Arteries carry blood from the heart to the peripheral district, deeper than veins and they 
branch out in numerous vessels with a decreasing calibre (from 25 mm in aorta to 0.2 
mm in small arteries). Capillaries are very small, with a thin wall composed of a single 
layer of endothelial cells and create a huge net that permit gaseous exchange between 
blood and tissues. Veins carry blood from periphery to the heart, they have a major 
calibre and near the heart their wall structure is almost similar to arteries even if less 
elastic. 
 
1.1.1 Artery composition 
Arteries wall is constituted by 3 concentric laminas: Internal Laminae (intimal), Medial 
Laminae (mesoartery) and External Laminae (adventitia). Between those laminae, as 
bounds, there are 2 other laminae of elastic tissue, called inner elastic and outer laminae 
Intimal Tunica  
The most internal layer, in close contact with flowing blood; it is constituted by single 
line of endothelial cells that are overlooking to the longitudinal axis of the vessel. 
Endothelial cells lean on a thin layer of loose connective tissue, or sub-endothelial 
laminae, rich in elastic fibres that clump together forming the inner elastic lamina.  
 
Medial Tunica  
The intermediate layers. It is constituted of smooth muscle cells in a matrix rich in 
elastic fibres, collagen and proteoglycan; those components are always present in the 
vessel wall, their amount is different according to the area in which they reside. In the 
medial tunica the activation of the sympathetic system determine both contraction and 
consequent reduction of vessel calibre (vasoconstriction) and relaxation and consequent 
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increase of vessel diameter (vasodilatation). 
 
Adventitial Tunica  
The most external layer, it is a loose connective tissue rich in collagen fibres sprawling 
orientated, just few inflammatory, smooth muscle cells and adipocytes. It can be 
considered a connective sheath with a restraint role. In large and medium calibre vessels 
the adventitial tunica is more developed to hold in his thickness vasa vasorum (small 
vessels drizzling and feeding vascular wall) and nerva nervorum (vegetative 
sympathetic fibers controlling mainly the smooth muscle fibres of the medial tunica).  
 
 
 
FIG.3 Vessels composition and difference 
 
 
 
From the heart to peripheral capillaries the blood flows through a network of arteries 
with a decreasing diameter; distinguished by their size and structural characteristics in 
large-calibre elastic artery, medium-calibre muscular artery and small-calibre artery.  
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1.2 Vascular Tissues 
1.2.1 Endothelial Tissue 
Endothelial tissue is a mesenchymal-derived connective tissue, similar to the endothelial 
layer of the interior surface of vessels. Endothelial cells are very flat, have a central 
nucleus and with a diameter of about 1-2 µm. They form flat, pavement-like patterns on 
the inside of the vessels and at the junctions between cells there are overlapping regions 
that help to seal the vessel. Endothelial cells contain just few intracellular organelles 
(Golgi apparatus, mytochondria, endoplasmatic reticulum and free ribosome), numerous 
pinocytosis vesicles to carry nutrients through the endothelium, and the characteristic 
Weibel-Palade electrondense granules. Those secretory granules have a role in the 
coagulation as they contain the von Willebrand factor (VIII factor of the coagulation). 
Endothelium was erroneously considered as a simple covering layer, but now it is 
known that elaborating several active molecules acquire the ability to modulate the 
activity of the vessel wall (Nitric Oxide; Endothelin) and to cooperate with blood cell 
and coagulation proteins in contact with the luminal surface. Besides endothelial cells 
have an important role in the inhibition of the formation of thrombosis or hyperplasia, 
and are essential to guarantee homeostasis and the maintenance of vascular integrity. 
Endothelium is in direct contact with blood flow and a target for both mechanical and 
hormonal signals, it is fundamental in the control of microcirculation arteries function. 
Shear stress and Tense stress are the two mains mechanical forces induced from blood 
on the vessel wall. Shear stress is caused by the laminar flow attrite mainly on 
endothelial cell; Tense stress is caused by the hydrostatic pressure into the vessel. The 
final effect is the modulation of contraction relaxation phenomena in the vessel 
depending on the blood flow. 
 
1.2.2 Muscular tissue 
Smooth muscle is an involuntary non-striated muscle, found within the tunica media 
layer of arteries and veins. Smooth muscular tissue is composed by spindle-shaped cells 
with a central nucleus and characterized by abundant sarcoplasm and a less content of 
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myoglobin protein. SMCs don’t present transversal muscular stripes because 
myofilaments, which run along cells major axis, are disposed in an irregular way. 
 
1.2.3 Connective tissue 
 
Connective tissue is the most different of the four tissue types with a wide variety of 
functions. It ranges in consistency from the gel-like softness of areolar connective tissue 
to the hardness of bone. Connective tissue (CT) forms an extensive compartment in the 
body and can be considered as the "glue" that holds the body together. Connective 
tissue consists of cells and extracellular material secreted by some of those cells. Thus, 
unlike the other basic tissues (epithelia, muscle, nervous), the cells in CT may be widely 
separated from one another within the extracellular matrix. In many types of connective 
tissue, the matrix-secreting cells are called fibroblasts assigned to formation and 
maintenance of the matrix. An abundance of other cell types with different functions 
may also be present like defence (macrophages, mast cells, lymphoid cells) and specific 
functions (adipocytes). Fibroblasts are the principal cells of connective tissue. They are 
responsible for the secretion of all types of fibres (collagen, reticular, elastin) and the 
complex carbohydrates of ground substance. A single fibroblast is believed to be able to 
secrete all the extracellular components, both sequentially and simultaneously. In 
histological preparations, only the nucleus of the fibroblast can be identified, the 
cytoplasmatic processes blend in with the surrounding collagen. After the biosynthetic 
activity fibroblast become fibrocytes.  
There are three types of fibres secreted by connective tissue cells: collagen 
fibres, reticular fibres, and elastic fibres. The abundance and preponderance of different 
types of fibres varies in different CTs.  
Collagen fibres: The most common fibre type is the collagen fibre. These are flexible 
fibres with a high tensile strength. At light microscope (LM), they appear as wavy lines 
of variable width and indeterminate length.  
Reticular fibres: Reticular fibres are closely related to collagen fibres. They are made of 
type III collagen fibrils (sometimes in association with type IV collagen). The 
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individual fibrils that constitute the reticular fibre are of narrow diameter and typically 
do not bundle to form thick fibres. 
Elastic fibres: Elastic fibres are thinner than collagen fibres and are arranged in a 
branching pattern to form a three dimensional network. They give tissue the ability to 
cope with stretch and distension. Elastic fibres are interwoven with collagen fibres in 
order to limit distensibility and to prevent tearing (FIG.4). 
 
 
FIG.4 Diagram of vascular tissues 
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2. REGENERATIVE MEDICINE 
 
Regenerative medicine and tissue engineering is an emerging and growing 
multidisciplinary field, involving knowledge in biology, medicine biotechnology and 
bioengineering, and focused on the repair, replacement or regeneration of cells, tissues 
or organs to restore impaired function resulting from any cause, including disease, 
trauma, congenital defects and aging. This field holds the promise of using the body’s 
natural healing process to regenerate damaged tissues and organs, previously irreparable 
or to accelerate and secure the healing process with stem cell therapy and by the 
association with constructs apt to promote natural repair mechanism of biological 
tissues or to replace them. Tissue engineering has an important role in the development 
of regeneration field, thanks to the association between engineering and biological 
knowledge it is possible to realize specific constructs (FIG.5). A construct has to satisfy 
two important requisites. The scaffold, a biological structure that allows cells and 
extracellular matrix (ECM) growth and tissue assembly, and the cellular component 
able, in vitro and in vivo, to adhere and grow after seeding into the scaffold.  
 
 
 
FIG.5 Triage of Tissue Engineering 
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Scaffolds must be biocompatible-materials, they can be natural or synthetic, with 
different structures according to the specific application they are made for. Scaffolds 
should hold cells, permit their adhesion in order to promote cell proliferation and 
differentiation. Instead cells are the active component in the construct, after their 
adhesion they start to proliferate, synthesize and depose specific matrix of the interested 
organ.  
 
 
2.1 Highlights of  Regenerative Medicine and Tissue Engineering 
 
Alexis Carrel, a French surgeon and biologist, is considered the father of modern 
cardiovascular and transplant surgery. His visionary studies on cell culture and ex vivo 
organ preservation and growth anticipated concepts regarding tissue engineering and 
regenerative medicine. His investigations and his collaborative friendship with the 
aviator and engineer Linbergh brought in 1930 to the development of the first perfusion 
pump, which allowed living organs to exist outside of the body during surgery, opening 
the way to organ transplantation. Their invention was a crucial step in the development 
of perfusion systems for cardiac and transplant surgery, and for bioreactors currently 
used in regenerative medicine and tissue engineering investigations. Tissue engineering 
and regenerative medicine remained quiescent for the next 30 years after Carrell’s 
death, during this time, several studies permitted the translation of findings from the 
bench to the bedside in the field of organ transplantation, which may be considered as 
one of the first forms of cell therapy in the history of medicine. Vacanti et al. in 1988 
published one of the first tissue engineering experimental studies. In this study, were 
seeded fetal and adult rat and mouse hepatocytes, pancreatic islet cells, and cells from 
the small intestine onto synthetic scaffolds. These scaffolds were made of synthetic 
polymers organized into fibres networks that reproduced the extracellular matrices 
present in all organs that allows cells to remain viable by diffusion, promotes vascular 
ingrowth, and permits cellular proliferation. The following years were characterized by 
several variations and implementation of this principle and numerous tissues were 
constructed and implanted (Orlando G. et al, 2011). In the early 1990s tissue 
engineering principles combined with the increasing studies of adult stem cells and ESC 
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(Deans	  et	  al,	  2000,	  Pittenger	  et	  al,	  1999)	  unified	   these	  apparently distinct fields of 
science in one concept, the regeneration of living and functioning body parts destined to 
replace diseased or damaged cells, tissues, or organs. More often the terms 
“regenerative medicine” and “tissue engineering” are used as synonymous, but it’s 
important to note that “regenerative medicine” indicate a field in the health sciences that 
aims to replace or regenerate human cells, tissues, or organs establishing normal 
function. This process may require cells, natural or artificial scaffolding materials, 
growth factors, or combinations of all three elements. “Tissue engineering” is a field of 
science that result by a combination of cells, engineering and materials methods and 
biochemical factors to improve or replace biological functions (FIG.6). Tissue 
engineering was also been defined as “understanding the principles of tissue growth, 
and applying this to produce functional replacement tissue for clinical use” (MacArthur 
et al, 2005).  
 
 
Fig.6 Example of tissue engineering as applied to various organ system 
 
 
2.2 Tissue Engineered Blood Vessels 
 
The main goal of a Tissue Engineered Blood Vessel (TEBV) is to create an autologous 
vascular graft for bypass surgery. However engineered blood vessel are also use in 
preclinical device evaluation. Tissue engineering manipulates material properties to 
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produces a unique configuration to mimic a specific tissue. 
 
 
2.2.1 Highlights of Tissue Engineered Blood Vessels 
 
The first report of vascular tissue engineered graft was in 1986 when Weinberg and Bell 
developed a vessel composed primarily of biological components: bovine smooth 
muscle cells (SMCs), and fibroblasts on a layer of collagen (Song Li et al, 2011). The 
collagen and SMCs were jelled together using a casting media to create a tubular lattice. 
After a week a Dacron sleeve was placed around the exterior of the tissue engineered 
‘media’ and seeded with fibroblasts to enhance mechanical properties of vessel and 
mimic the adventitia. After another two weeks were seeded endothelial cells and left in 
culture for one week. After this period the central mandrel was removed and they 
obtained a tubular structure similar to a vessel.  The mechanical strengths along with the 
scaffold structure of this vessel mimicked the mammary muscular artery, representing 
the first TEBV with increased physiological relevance and durability.   
This first experiment was followed by several others studies, Foxhall et al., for example, 
worked with different coatings to promote endothelization. Endothelial cells were 
seeded on the luminal surfaces of Dacron coated with collagen and fibronectine the 
result was a surface that significantly increased the proliferation of endothelial cells. 
The obtained scaffold had similar in-vitro properties as a mammalian muscular artery 
and could be used to study the cellular interactions with a vascular ECM.  
In 1998 L’heureux et al. developed a construct utilizing a simple collagen sheet on 
which were seeded human vascular SMCs, the sheet was put around a small mandrel to 
represent the media of a vessel.  Then a similar sheet seeded with fibroblasts was put 
around the exterior of the SMCs, to mimic the adventia. Finally, the mandrel was 
removed and the lumen was seeded with ECs. L’heureux et al. developed a completely 
biologic vessel and with the potential for natural remodelling and reduction of foreign 
body reactions, but unfortunately, this model had limited mechanical strength 
(L’heureux et al, 1998; Shaikh F.M. et al, 2008). 
The development of these and several other scaffold types put the bases for the creation 
of future TEBVs. Many researchers worked to create countless types of tissue-
engineered grafts with the purpose to develop a model exportable into clinical 
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applications for cardiovascular disease. 
Through the development of TEBV, several qualities have been identified to be 
extremely important to the graft function. As said before, the scaffold has to give a 
comfortable ‘living environment’ for cells, its structure should have small fibres 
randomly interconnected to permit the cells to anchor and encourage strong cell 
adhesion and proliferation. Scaffold must be microstructure that closely mimics the 
native ECM.  
 
 
2.3 Synthetic scaffold 
 
Scaffolds play a critical role in tissue regeneration and repair, in particular synthetic 
polymeric biomaterials act as synthetic frameworks referred as scaffolds, matrices, or 
constructs. Polymeric scaffolds have unique properties such as high surface-to-volume 
ratio, high porosity with very small pore size, biodegradation, and mechanical property. 
They offer distinct advantages of biocompatibility, versatility of chemistry, and the 
biological properties which are significant in the application of tissue engineering and 
organ substitution (Brahatheeswaran D. et al, 2011). Synthetic polymers are largely 
divided into two categories: biodegradeable and nonbiodegradeable. Some synthetic 
biodegradeable polymers are the family of poly(α-hydroxy esters) such as polyglycolide 
(PGA), polylactide (PLA) and its copolymer poly(lactide-co-glycolide) (PLGA) 
(Kakisis J. et al, 2005). Non-degradable synthetic polymers which are most often 
utilized in a TEBV are poly(ethylene terphalates) [Dacron] and ePTFE. Dacron and 
ePTFE are both a highly crystalline and hydrophobic material, that reduce the overall 
elusion of particles and structural integrity. Scaffold properties can be changed by 
manipulate the components of the polymer structure. This manipulation will contribute 
to cells interaction with the scaffold and to facilitate cells anchoring (Brett C. et al, 
2005; Lovett M. et al, 2010). Even if these synthetic materials have been wildly used in 
bypass procedures a high rate of thrombosis formation has limited their use as small-
diameter vascular grafts. In efforts to overcome these limitations, several tissue 
engineering approaches have been developed to prepare functional small diameter 
vessels in vitro (Peck M. et al, 2012). These techniques include culturing vascular cells 
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on a collagen matrix or other biodegradable synthetic scaffolds, such as polyglycolic 
acid (PGA). PGA along with other degradable scaffolds can be manufactured to have 
unique microstructures. Scaffold microstructure alterations may include increased 
porosity for better cell adhesion, a variety of degradation profiles for drug delivery or 
integration with the host, as well as specific mechanical properties for improved 
surgical handling or overall strength improvement (FIG.7). However, these tissue-
engineered vascular grafts either lack sufficient mechanical strength or require long 
culture periods to obtain the mechanical strength that is required for implantation and 
are thus cost-and labor-intensive (Liqiong G. et al, 2009).  
 
 
FIG.7 Synthetic graft 
 
 
2.4 Biological scaffold 
 
Recently, an alternative tissue engineering approach involving the decellularization of 
native tissues has shown success in a variety of applications. Decellularized tissues are 
composed of natural extracellular matrix (ECM) and have the advantage of maintaining 
the structure and mechanical properties of native tissues. The idea of using 
decellularized vessels in this manner has been around for at least 2 decades, but 
attempts at recellularizing this material are more recent and are now one of the more 
common tissue-engineering technologies (Stagemann J.P. et al, 2011). 
In 1960 a group of researchers using primary tissues developed a scaffold by cross-
linking the tissue, the immunogenic effects was reduced enough to create a viable 
scaffold source. Even though mechanical properties were lost and cell death occurred. 
In 1989 Laka et al. decided to use a detergent to break cellular bonds from the ECM, 
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leaving an acellular, biological graft. From this original paper, many other researchers 
further developed the decellularization process.  There are many applications for which 
decellularization may be utilized; essentially any tissue that can be isolated can be 
decellularized.  The major benefit of decellularization is not only the potential to create 
scaffold with ideal microstructure and mechanical properties, but also limit 
immunogenic effects of a graft and increase the potential tissue sources. 
Decellularized biomaterial can be seeded with various cardiovascular cells, including 
endothelial cells, progenitor cells, and myocardial cells, to generate functional tissues, 
including blood vessels and other tissues. Additionally, decellularized tissues have the 
potential for repair, growth, and remodelling in vivo. 
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3. DECELLULARIZATION 
 
Decellularization is the systematic removal of all cellular and nuclear components from 
tissues (cytoplasmatic material, membrane pieces and nucleic acid) to leave the 
complex mixture of functional and structural proteins that form the native ECM 
Decellularization itself can partially damage the ECM, the removal process must be 
gentle enough to minimize its effects on the composition, biological activity, and 
mechanical integrity of the remaining ECM  
Decellularization methods result often in a combination of chemical, physical and 
enzymatic techniques. Physic treatment as sonication, shaking, frozing-defrozing, are 
commonly used together with chemical solutions. The combinations between those 
methods permit the fragmentation of cell membrane and the consequent lost of cell 
contents. 
Enzymatic treatments are usually done with trypsin a solution indicated for the rupture 
of intercellular and intracellular bound and transmembrane proteins. Fragmentation of 
membranes is realized with detergents and ionic solutions.  
Decellularization protocols must guarantee cell membrane lysis (ionic solutions or 
physic methods); separation of cellular material from the proteins on ECM (enzymatic 
treatment or detergents); elimination of cellular rest from matrix structure. Mechanical 
treatment such as shaking or high pressure can be added to improve decellularization 
process. 
There are several chemical solutions like alkaline and acid treatments, ionic or non-
ionic solutions, zwitteronic solutions, hypotonic or hypertonic solutions. All those 
method can both be useful and damaging, it is important to choose the appropriate 
method for each tissue we want to decellularize.  
Alkaline and acid solutions are very efficient and act as disinfectant against eventual 
microorganism infection on the construct, but unlikely is also too aggressive for the 
ECM, in which cause the rupture of peptides as GAG in collagene tissues.  
Ionic detergents are efficient to solubilise both cytoplasmatic and nuclear waste 
materials, but they can damage some proteins too. The most used is Sodium 
DodecylSulphate (SDS), very efficient for the removal of cellular debris, it doesn’t 
damage collagene fibres but it can damage GAGs and small proteins. 
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The most used zwitteronic detergent is CHAPS (3-[(3-Cholamidopropyl)-
dimethylammonio]-1-propane sulfonate) harmful for the ECM but optimum for the 
decellularization of vessel endothelium as do not damage collagen and elastic fibres. 
Hypotonic and hypertonic solutions generate osmotic shocks causing cells lysis; this 
treatment has to be used together with other detergent that eliminate cell debris.  
After each decellularization process it is necessary to wash tissues with neutral solution, 
physiological solution or PBS, to avoid the persistence in the scaffold of cells material 
compromising the following cellularization. 
 
 
3.1 Cellularization  
 
Choose the right cell line to seed on the scaffold is the key of tissue regeneration. There 
are several methods used for cells seeding as injection, simple seeding or induction to 
migrate in it. Following proliferation and matrix deposition according with the 
phenotype, determine new tissue formation. Adult Stem Cells (ASCs) gained 
researcher’s interest because they are undifferentiated cells characterized by self-
renewal and ability to differentiate in almost all specialized cells types related to the 
tissue or organ. ASCs reside in all developed organisms, maintaining and repairing 
tissues in which they reside, as bone marrow, brain, heart, blood vessels etc. 
(Barrilleaux et al.2006, Gimble et al. 2007). Those characteristics render ASCs possible 
candidate for transplantation-based therapies. The most important alternative cells 
source for tissue regeneration especially for vascular tissue engineering are autologous 
human mesenchymal stem cells (hMSCs). 
 
 
3.1.1 Mesenchymal Stem Cells 
 
Mesenchymal stem cells were discovered in 1960 by Friedenstein, who identified in 
bone marrow two population of stem cells: Hematopoietic Stem Cells (HSCs) 
precursors of blood cells, and Mesenchymal Stem Cells (MSCs) precursors of cells 
supporting the formation of blood and fibrous connective tissue and bone, cartilage and 
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fat cells (Friedenstein et al,1974). MSCs are an archetype of multipotent adult stem cell 
able to differentiate into several mesodermal cells, like chondrocytes, osteocytes, 
adipocytes, myocytes and bone marrow stromal cells (Deans et al., 2000, Pittenger et al, 
1999). Differentiation potential and tolerogenic properties confer to MSCs a promising 
role in future application in regenerative medicine field. One potential advantage of 
hMSCs lies in their harvest ease and large availability, they have been isolated from 
several tissues, including bone marrow (Pittinger et al, 1999), umbilical cord blood 
(Erices et al, 2000, 2003), peripheral blood, adipose tissue vascular wall (Pasquinelli G. 
et al, 2010) and placenta (Schdmidt. et al, 2009; Evangelista M, 2008), solving ethical 
and legal concerns. Moreover hMSCs present advantages over other type of stem and 
progenitor cells for the other following reasons: (1) long-term crypreservation; (2) 
extraordinary plasticity, (3) easy genetic manipulation (Moby V. et al, 2010). 
hMSCs have a fibroblast-like morphology, they are characterized by adherent growth 
on plastic and expansion under specific culture conditions, they were defined by a panel 
of non-specific surface antigens and by their in vitro e in vivo differentiation potential 
(Javazon et al., 2004). The gold standard assay utilized to identify MSC is CFU-F assay 
that identifies adherent, spindle-shaped cells that proliferate to form colonies 
(Friedenstein et al., 1970). hMSCs, were initially isolated as the plastic adherent 
fraction of bone marrow (Friedenstein et al., 1970). A Percoll density gradient was used 
to remove unwanted cell types, present in the bone marrow aspirate, and hMSCs were 
just a small percentage (estimated at about 0.001-0.01%).  
Mononuclear cells are isolated with a gradient centrifugation and seed with fetal bovine 
serum (FBS). The adherent fraction is expanded in a limited number of passages (Ulloa-
Montoya et al., 2005). 
 
 
The Mesenchymal and Tissue Stem Cell Committee of the International Society for 
Cellular Therapy (Dominici et al., 2006) proposed a pathway of antigen to define 
MSCs: 
- CD105 identifies an epitope of endoglin (CD105), the Transforming growth 
factor beta (TGFβ) receptor III present on endothelial cells, erythroblasts, 
monocytes, and connective tissue stromal cells, it helps the enrichment of 
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stromal progenitors from bone marrow (Short et al., 2003);  
- CD73 a glycoprotein, identified by monoclonal antibody SH3 and SH4, 
involved in B-cell activation (Short et al., 2003) and expressed in lymphocytes 
and endothelial cells. 
-  CD90 or Thy1: a 25–37 kDa N-glycosylated, glycophosphatidylinositol (GPI) 
anchored conserved cell surface protein, originally discovered as a thymocyte 
antigen. Thy-1 can be used as a marker for several stem cells and for the axonal 
processes of mature neurons. Structural study of Thy-1 lead to the foundation of 
the Immunoglobulin superfamily.  
 
MSCs are negative for other markers of the hematopoietic lineage including CD34 
considered a primitive HSCs marker (a transmembrane protein that defined ˜ 1% of 
normal bone marrow mononuclear cells including hematopoietic precursors/stem cells 
and normal endothelial); CD31 (a glycoprotein designed also platelet endothelial cell 
adhesion molecule-1 (PECAM-1) normally expressed on endothelial cells, circulating 
and tissue hematopoietic cells including platelets, monocytes/macrophages, 
granulocytes and B-cells); CD45 (recognizes a family of proteins known as the 
leukocyte common antigens expressed on the surface of almost all haemato-lymphoid 
cells and their progenitors) and CD14 or CD11b (an immune cell marker).  
Stro-1 is a well know MSC marker, Stro-1 negative cells are not able to form colonies. 
Stro-1 positive cells can become HSC-supporting fibroblasts, smooth muscle cells, 
adipocytes, osteoblasts and chondrocytes (Dennis et al., 2002). In addition, the 
expression of Stro-1 distinguishes two populations of MSCs with different location and 
HSC-supportive abilities (Bensidhoum et al., 2004). However, Stro-1 is not specific for 
these cells and its expression in MSCs is gradually lost during culture expansion 
(Gronthos et al., 2003) so Stro-1 labelling is possible only during early passages. 
After their discovery, several studies demonstrated the multilineage differentiation 
potential of MSCs populations showing their capacity to develop into differentiated 
mesenchymal phenotypes including bone (Bruder et al., 1997), cartilage (Kadiyala et 
al., 1997), tendon (Young et al., 1998), muscle (Ferrari et al., 1998), adipose tissue 
(Dennis et al., 1999) and hematopoietic-supporting stroma (Prockop et al., 1997) and 
showing also a high degree of plasticity (D’Ippolito et al., 2004, Zhao et al., 2002) 
(FIG.8). 
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MSCs easy isolation technique and their expansion potential, migratory capacity and 
immunosuppressive ability made them a popular cell type for regenerative medicine, 
gene therapy and tissue engineering. 
Several studies on animal transplantation shown that ex-vivo expanded MSCs were able 
to differentiate into cells of the residing tissue, to repair damaged tissue and to restore 
partially its normal function, generating promising results for the treatments of several 
illness, including bone (Mauney et al., 2005), cardiovascular (Zimmet et al., 2005) and 
brain disease (Zimmet et al., 2005). Moreover it seems that MSCs have paracrine 
activity, the bioactive factors produced can suppress the local immune system, inhibit 
apoptosis and enhance angiogenesis (Caplan et al., 2006). 
 
 
 
FIG.8 Plasticity and mesengenic process of MSCs 
 
 
 
 
3.2 Tissue-engineering bioreactors 
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A bioreactor is a system or device with the purpose to simulate an active environment 
that is close to a biological system. The use of bioreactors in tissue engineering field is 
widely increasing for the several following advantages: (1) facilitate cell seeding 
procedures on both sides of a 3D tubular matrix; (2) allow seeding and culturing of 
different cell types on either side of the tubular scaffold; (3) enhance oxygenation of the 
culture medium and mass transport (oxygen, nutrients and catabolites) between the 
medium and the adhering cells; (6) stimulate the cells with hydrodynamic stimuli, 
favouring the metabolic activity and the differentiation process; (7) allow the 
achievement and maintenance of sterility and other criteria of Good Laboratory Practice 
(Asnaghi M. et al, 2009). Bioreactors are normally made of Plexiglas and the system 
consists of three different chambers: air chamber I, cell culture medium chamber II, and 
cell-seeding and perfusion chamber III. The tissue-engineered conduit is surrounded and 
continuously perfused by cell culture medium that is recirculating through a closed loop 
connected to a reservoir filled with cell culture medium. The whole system can be 
placed in a regular humidified incubator at 37°C and 5% CO2 and air driven by a 
simple dual-phase control ventilator, which is placed outside the incubator and 
connected to the air chamber of the bioreactor by a single silicone tube (FIG.9). To 
establish various pulsatile flows and biomechanical stresses it’s necessary to adjust the 
stroke volume, the stroke rate, and the inspiration/expiration time of the ventilator. The 
flow rates ranged from 100 mL/min to 3 L/min, pressures ranged from 3 to 150 mmHg, 
and shear stress (t) ranged from 1.12 to 32.45 dyn/cm2 (Sodian et al, 2002).  
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FIG.9 Example of flow-pump-bioreactor 
 
 
The main advantage in the use of bioreactors in the production on vascular tissue 
engineered graft is that the perfusion system mimic the physiological flow of 
cardiovascular system, and more over is possible to produce vascular grafts in a manner 
that is reproducible, so that not only each graft is the same, but also so that the 
bioreactor produces the same cell derived graft each time it is used. 
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EXPERIMENTAL DESIGN 
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4. AIM OF THE STUDY 
 
This Introduction has described the background for which this thesis is based. 
In cardiac or peripheral bypass surgery, diseased arteries are replaced with autologous 
veins or, less frequently, arteries. However more often patients in need of bypass 
surgery do not have suitable vessels or absence of veins as replacement due to the 
systemic vascular disease. In clinical practice are commonly used synthetic vascular 
prothesis that are good conduits in high-flow low-resistance conditions such as large 
peripheral arteries, but have difficulty in their performance as small diameter vessel 
grafts. 
Based on published use of decellularized tissues as biologic scaffolds, this thesis 
explored the development of decellularized human vessels for use as tubular graft. 
Cell-free vessels are expected to have more biocompatibility when compared to 
synthetic vascular conduits; and are optimal natural 3D matrix templates for driving 
stem cell growth and tissue assembly in vivo. 
To investigate the potential use of these cell-free conduits as scaffold in this thesis will 
be discussed three main aspects: establishment of a decellularization protocol, 
mechanical characterization of the decellularized scaffold, and finally re-cellularization 
of the scaffold. 
 
The following is a summary of the specific aims pursued in this thesis. 
- Aim 1: Establish a decellularization protocol for the complete decellularization 
of human arteries and evaluate the success of the decellularization protocol 
using histology. 
- Aim 2: Determine the ability of the decellularized scaffold to maintain the native 
mechanical properties by assessing the ECM matrix with TEM analysis. 
- Aim 3: Develop a protocol to recellularize the scaffold, by evaluating the right 
cell type and preconditioning it in appropriate bioreactors. 
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5.  MATHERIAL AND METHODS 
 
5.1 Decellularization Protocol Development 
 
All vessels, fresh and cryopreserved, were harvested from heart beating (HB) and non-
hearth beating (NHB) donors at the Regional Bank for Cardiovascular Tissue of the 
Sant’Orsola/Malpighi Hospital. The chosen segments were femoral arteries and veins 
and carotid arteries.  
Harvested vessels were maintained for 72 hours in an antibiotic mixture (mefoxin 
240mg/ml, lincomycin 120mg/ml, colimycin 100mg/ml, vancomycin50 mg/ml); after 
decontamination were taken to the lab for cleaning, or the removal of all the connective 
tissue using a scalpel, razor blade, and scissors. 
Crypreserved vessels were first thawed in a 37°C water bath until the structure was 
malleable; both vessells were washed in physiologic solution (0,9 % sodium chloride) 
to eliminate DMSO in cryopreserved ones and antibiotic solution from the fresh ones. 
After all the procedures the vessels were ready to be used for any experimentation. 
The preliminary decellularization parameters were based on existing protocols in 
literature, including the duration of decellularization, detergents and temperatures. 
Protocol 1  
Short time protocol but too aggressive for the ECM. This protocol requires two 
incubations in two different sterile buffers.  
Buffer I: 0,1% Trypsin 0,02 ethylenediaminetetraacetic acid (EDTA) in PBS without 
Mg++ Ca++, for 36 hours at 37°C (all Sigma, St. Louis, Mo., USA). The 
trypsin/EDTAsolution was changed every 12 hours. 
Buffer II: 20 µg/ml RNase; 200 µg/ml DNase (Boehringer, Mannheim, Germany), for 4 
hours at 37°C.  
 
All incubations were conducted under continuous shaking. 
After the decellularization process the scaffolds were washed several times for removal 
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of residual substances with PBS and stored in sterile PBS at 4°C. 
 
Protocol 2 
Short time protocol but not very efficient. 
Buffer I: 0.1% SDS in distilled water, for 16 hours at 37°C 
Buffer II: 0.9% NaCl 3 passages for 3 hours each. 
All incubations were conducted under continuous shaking. After the decellularization 
process scaffolds were left in NaCl for 24 hours and after that washed in sterile PBS. 
 
Protocol 3  
A nonenzymatic protocol that associate hypotonic shock and low-concentration ionic 
detergent. 
Buffer I: Tris 10 mmol/L; 0.1%; ethylendiamine tetraacetic acid (EDTA) in distilled 
water, pH 8 for 14 hours 
Buffer II: 0.1% Sodium dodecylsulfate (SDS) for 24 hours 
Buffer III: Tris 50 mmol/L; NaCl, 0.15 mol/L; 0.1%ethylendiamine tetraacetic acid 
(EDTA) in distilled water, pH 8 for 24 hours. 
 
All incubations were conducted at 37°C under continuous shaking. 
 
 
 
5.2 Evaluation of decellularization process. 
 
Histology was used to evaluate the decellularization process 
 
5.2.1 Hematoxilin Eosin 
 
Samples were fixed in 10% formaldehyde solution, embedded in paraffin to obtain 
3µm-thick vessel sections for the histological staining. For conventional 
histopathological analysis sections were stained with hematoxylin & eosin (H&E) 
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according to the histological procedures and observed with LM. The staining method 
involves application of the basic dye hematoxylin which colours basophilic structures 
with blue-purple hue and the alcohol-based acidic eosin Y that colours eosinophilic 
structures in bright pink. Images were digitalized through a video camera (JVC 3CCD 
video camera, KY-F55B, Jokohama, Japan) connected with a Leitz Diaplan LM 
(Wetzlar, Germany); original images were taken at magnificatio 10X-20X and analyzed 
using the Image-Pro Plus® 6 software (Media Cybernetics, Inc., Bethesda, MD, USA). 
 
 
5.3 Histological evaluation of Extracellular Matrix  
 
5.3.1 Trichrome  
Trichrome Picro-Mallory (Bio Optica Milano SPA) stains some components of 
connective tissue according to the different degree of affinity between dyes and tissue 
macromolecules. In particular, connective tissue is markedly acidophil because of the 
presence of many basic groups. 3µm-thick paraffin embedded sections were brought to 
distilled water and processed for the trichrome staining following the Picro-Mallory 
Trichrome manufacturer’s instruction.  
 
5.3.2 Weigert Assay 
Weigert Van Gieson (Bio Optica Milano SPA) is a combination of stains used in 
histology to identify elastic fibres. The method is based on the affinity towards elastic 
fibers displayed by resorcin fuchsin, a precipitate resulting from a reaction between 
resorcin and basic fuchsin and ferric chloride. 3µm-thick paraffin embedded sections 
were brought to distilled water and processed for the weigert staining following the 
Weigert Van Gieson manufacturer’s instruction. 
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5.4 Ultrastructural evaluation of Extracellular Matrix 
 
5.4.1 Transmission Electron Microscopy 
To evaluate the integrity of ECM samples were washed with phosphate-buffered 0,15 
mol/L and fixed in 2.5% buffered glutaraldehyde and processed for transmission 
electron microscopy (TEM). Vascular tissue were rinsed in phosphate buffer and post-
fixed in 1% buffered Osmium Tetroxide for 1 hour at room temperature (rt) to preserve 
the lipid structures and cell membranes. After fixation samples were washed, 
dehydrated in a graded series of ethanol from 70% to 100% (3x10 minutes each at rt), 
dipped in propylene oxide (2x15 minutes at rt) and then embedded in epoxy resin (50% 
Araldite CY12 + 50% Araldite HY + 1,5% Benzyldimetylammina (BDMA) as 
accelerator; all purchased from TAAB, England). The semi-thin sections obtained with 
ultramicrotome were stained with Toluidine blue. Ultrathin sections were cut with 
diamond knives using an ultramicrotome, transferred to specimen support grids, 
counterstained with uranyl acetate and lead citrate and observed in a Philips 400T 
trasmission electron microscope. 
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6. RESULTS 
 
6.1 Haematoxylin Eosin 
 
In Figure 9, two images from each protocol are compiled together. All sections were 
stained with H&E and imaged at 5X and 10x magnification.   
 
 
FIG.9 Haematoxylin/eosin images of the different 
 decellularization protocols 
 
 
Protocol 3 (P3) was considered to be the optimal for the decellularization process. 
Hematoxylin Eosin stain showed that the decellularization solution P3 is optimal for the 
elimination of cells or cellular component, apparently without degrading the vessel wall. 
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6.2 Thricrome Picro-Mallory and Weigert stain  
 
In figures 10 and 11 are shown samples stained with Trichrome Picro-Mallory and 
Weigert. Here a comparison between control and cell-free samples, using the optimized 
decellularization protocol (P3).  
 
 
FIG.10 Trichrome Picro-Mallory Stain. A comparison between positive  
control (Ctr) and decellularized sections. In blue the collagen fibres. 
 
 
 
FIG.11 Weigert stain, A comparison between positive control (Ctr) 
 and decellularized sections. In black the elastic fibres. 
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Trichrome Picro-Mallory and Weigert stains showed that the decellularization protocol 
did not damaged the collagen and elastic fibres of the extracellular matrix (ECM). 
 
6.3 Transmission electron microscopy 
 
With transmission electron microscopy (TEM) was evaluated the ultrastructure of the 
collagen and elastic fibres to better investigate the integrity of the ECM (FIG.12).  
 
 
FIG.12 Collagen (A) and elastic (B,C)  
fibres in the ECM of a cell-free vessel  
 
From the ultrastructural analysis emerged that collagen fibres are not damaged by 
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decellularization solutions but it seems they were subjected to a change in their normal 
arrangement, maybe caused by the empty spaces left from the eliminated cells. 
Not any significant change was observed in the elastic fibres. 
 
  
7. ISOLATION OF MSCs 
 
7.1 Isolation of vascular wall mesenchymal stem cell from huma 
thoracic aorta 
 
Cells were obtained from thoracic aorta segments harvested from heart beating (HB) 
and non-hearth beating (NHB) donors. Several pieces of thoracic aorta tissue were 
washed with sterile Hepes, mechanically minced and enzymatically digested with 0.1% 
collagenase type II (Sigma,Milan, Italy) in Hepes at 37°C for 40 min. The homogenate 
was subsequently pelleted by centrifugation at 1600 rpm and washed twice in PBS; the 
cells were then counted and plated at 1x106/cm2 in collagen biocoated culture flasks 
(BD Labware, Franklin Lakes, NJ) in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 20% heat inactivated FBS and antibiotics (100 U/ml penicillin and 
100 µg/ml streptomycin), and incubated at 37 °C in a humidified atmosphere with 5% 
CO2. After one week the non-adherent cells were removed by replacing the medium 
supplemented with 10% FBS. When the cultures were near confluence (approximately 
1-2 weeks) the cells were detached by treatment with 0.25% trypsin-EDTA (Sigma) and 
were expanded up to passages 12- 15. 
 
 
7.2 Isolation of myofibroblast from human umbilical cord 
Human umbilical cord cells were harvested from fresh umbilical cords of healthy 
individuals after the obtainment of informed consents; human umbilical cord tissue was 
excised by biopsy from Wharton’s jelly, washed with PBS and minced into pieces of 
approximately 8 mm3. The tissue was then placed into petri-dishes and cultured in a 
humidified incubator at 37°C with 5% CO2 in advanced DMEM medium (Gibco, 
Invitrogen) after few days supplemented with 10% fetal bovine serum (PAN Biotech, 
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Germany), 2mM Glutamax (Gibco) and Gentamycin (50µg/ml, PAN). After one week 
the non-adherent cells were removed by replacing the medium supplemented with 10% 
FBS. Umbilical cord myofibroblast cells (ucMFBs) were expanded up to passage 11. 
 
 
7.3 Cells Characterization 
 
7.3.1 Cytofluorimetry  
 
Flow cytometer is able to analyze several thousand of cells every second and actively 
separate and isolate cells with specified phenotype. To detect surface antigen, cells 
taken at P3-P5 were washed twice with PBS containing 2% FBS and incubated for 20 
minutes at room temperature using the following extensive conjugated moAbs panel: 
anti-CD29-fluorescein isothiocyanate (FITC), anti-CD31-phycoerythrin (PE), anti-
CD34-PE, anti-CD146-PE, anti-CD44-FITC, anti-CD45-allophycocyanin (APC), anti-
CD73-FITC, anti-CD90-phycoerythrin-cyanine 5 (PC5), anti-CD105-PE, anti-CD117-
FITC (all from Beckman Coulter), anti-CD133-PE (Milteny Biotech) von Willebrand 
Factor (vWF, clone F8/86, Dako Cytomation), anti-KDR (Sigma), anti-NG2 (R&D 
System, Inc., MN, USA), anti-STRO-1 (clone STRO1, R&D System), anti-Notch-1 
(clone C-20, Santa Cruz Biotecnology), anti-Oct-4 (clone C-10, Santa Cruz 
Biotecnology) and anti-Sca-1 (clone CT-6A/6E, Cederlane Laboratories). Secondary 
moAbs were used after cell staining with unlabeled primary moAbs: anti-mouse IgG-
APC (Beckman-Coulter), anti-rabbit IgG-FITC (Dako Cytomation). For vWF and Oct-4 
revelation cells were fixed and permeabilized with the IntraPep Kit (Beckman-Coulter) 
and then incubated with anti-mouse IgG-FITC (Dako Cytomation). Negative controls 
were performed using appropriate conjugated non-relevant antibodies. Samples were 
analyzed using a Cytomics FC500 flow cytometer equipped with two lasers for data 
acquisition (Beckman Coulter). Results were analyzed using the CXP Software 
(Beckman Coulter). 
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7.3.2 Immunofluorescence 
 
Cells were plated at 1x103 in 24 well culture dishes (Cellstar), cultured until near 
confluence, and fixed in 4% paraformaldehyde in PBS for 10 min. at room temperature. 
For intracytoplasmic protein staining, cells were permeabilizated with 0.2% Tryton X-
100 in PBS. Unspecific staining was blocked by incubating cells with 5% Goat Serum 
in 1% Bovine Serum Albumine (BSA) in PBS for 30 min. at room temperature. The 
samples were then incubated sequentially with MoAbs for 60 min. at room temperature; 
MoAbs included the following: CD44 (1:50, Santa Cruz), CD90 (1:100 Biolegend), 
CD166 (1:50, Biolegend), Oct4 (1:20), CD146 (1:500), CD31 (1:10, Biolegend) and 
CD45 (1:200, Biolegend). Samples were rinsed three times with PBS and then 
incubated for 45 min at room temperature with the following secondary MoAbs: Cy2-
G-a-M (1:100, Jackson ImmunoResearch) and Alexa Fluor 546-Phalloidin (1:50, 
Invitrogen); Nuclei counterstaining was performed with DAPI (1:200, Sigma-Aldrich). 
Negative controls were performed omitting the primary antibodies.  
After three washes samples were mounted with the anti-fading reagent Lisbeth’s 
embedding medium (0.1 M Tris-HCl pH 9.5; Glycerol containing 50mg/ml n-propyl 
gallate). Samples were observed under a Leica fully automated inverted fluorescence 
microscope DMI6000 B using a DAPI filter (Leica Microsystems, Milan, Italy). 
 
 
7.4 Molecular analysis 
 
7.4.1 RNA extraction and RT-PCR 
 
Total RNA was isolated from human umbilical cord myofibroblast-derived cells using 
RNeasy Mini Kit (Qiagen, GmbH, Hilden, Germany) following the manufacturer’s 
instruction, and reverse-transcribed into cDNA (ThermoScript RT-PCR System, 
Invitrogen, Carlsbad, CA USA), which was used for PCR amplification with Taq 
polymerase (Bio Therm DNA Polymerase, GeneCraft GmbH, Ludinghausen, 
Germany). 
The primers sequences for Oct4 were: forward 5‘cgaccatctgccgctttgag 3’ and reverse 5’ 
ccccctgtcccccattccta 3’ (577pb). For NANOG forward 5’ cagaaggcctcagcacctac 3’ and 
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reverse 5’ ctgttccaggccaggcctgattgtt 3’(214bp). For SOX2 forward 5’ 
cccccggcggcaatagca 3’ and reverse 5’ tcggcgccggggagatacat 3’(448bp).  
Amplification of GAPDH (235pb; forward 5’ gaaggtgaaggtcggagt 3’ and reverse 5’ 
gaagatggtgatgggatttc 3’) was used as a positive control.  
The amplified fragments were analyzed by 2% agarose gel electrophoresis, GelRed 
stained. 
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8. RESULTS 
 
8.1 Cytofluorimetry 
 
Umbilicard cord myofibroblast isolated were analyzed for the single expression of 
characteristic markers generally used to identify the MSCs and stem cells using a flow 
cytometric analysis.  
Fibroblast-like cells were evaluated at their surface with a panel of antigens found in 
MSCs (CD90, CD44, CD105, CD29, CD73); hematopoietic lineage (CD45), 
hematopoietic progenitor (CD117, CD34, CD133), endothelial cells (CD31, vWF, 
CD146, KDR) and stemness markers (c-Kit, Notch-1, Oct-4, Sca-1, Stro-1) and perycite 
cells (NG2). As other mesenchymal stem cells, ucMFBs expressed typical 
mesenchymal antigens such as CD90, CD44, CD105, CD29, CD73 and NG2. On the 
contrary, they were negative for the early and mature hematopoietic markers CD34 and 
CD133 and for mature hematopoietic markers CD45. ucMFB were also negative for 
KDR, CD146, CD31 and vWF which are markers of differentiated endothelium whilst 
c-Kit was not detected. (FIG.13 A) 
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FIG.13 (A) Flow cytometry analysis of typical CD markers present on MSCs  
and typical hematopoietic and endothelial markers which are not expressed by MSCs 
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Cells expressed staminality markers such as Oct-4 and Notch-1; Sca-1and Stro-1 were 
also expressed although at lower level. (FIG.13 B) 
 
 
FIG.13 (B) Immunophenotype of staminality markers. 
 
 
 
8.2 Immunofluorescence  
 
In addition to flow cytometry analysis, a single immunofluorescence staining was 
performed to investigate the smooth muscle phenotype of ucMFB isolated. Cells were 
stained with intracytoplasmatic antigens against to smooth muscle markers (α-SMA, 
Calponin, h-Caldesmon, Vimentin, Desmin, and PDGF-rβ) and Ki-67 a proliferation‟s 
marker. The fibroblast-like cells showed a mesenchymal phenotype resulted positive for 
Vimentin and Calponin while, surprisingly, we observed rare cells positive for the α-
SMA staining and the absence of other smooth muscle markers like h-Caldesmon, 
Desmin and PDGF-rβ (FIG.14). 
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FIG.14 Immunofluorescence characterization of H-MSCs cultured on slide chambers. 
Cells were stained with moAbs directed against to smooth muscle markers. 
Negative control (A), α-SMA (B), Vimentin (C) and Calponin (D). Nuclei in  
blue and cell positive in green 
 
 
 
8.3 RT-PCR 
 
Gene expression of ucMFBs was evaluated by RT-PCR. This semiquantitative analysis 
confirmed that these cells expressed transcripts associated with embryonic stem cell 
marker, like Oct4 and NANOG. 
Both Oct4 and NANOG are transcriptor factors involved in the self-renewal of 
undifferentiated embryonic stem cells. Nanog, is also known as a key factor in 
maintaining the pluripotency. The presence of SOX2 expression was not detected in 
umbilical cord myofibroblast cells. 
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The positive control, BM-MSCs, expressed all the molecules of undifferentiated 
embryonic stem cells, Oct-4, NANOG, SOX2. GAPDH was used as housekeeping 
gene. 
 
FIG.15 Stem cell genes expression. On the left it is shown  
the transcript expression of Bone Marrow-derived cells;  
on the right it is shown the transcript expression of ucMFB 
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9. DEVELOPMENT OF RE-CELLULARIZATION 
PROTOCOL 
 
The aim of recellularization is to produce small diameter tissue engineered blood vessel 
(TEBV). For this purpose two different cell types were seeded on the cell-free blood 
vessels. vwMSCs and ucMFB were tested in their ability to adhere, penetrate and 
proliferate into the tissue. 
  
9.1 Static cellularization 
 
Decellularized vessels were cut into eight pieces of about 1cm2 each and placed in 12-
well dishes (FIG.16). Four of these segments were seeded with 1.2x106/cm2 vwMSCs at 
the eleventh culture passage, covered with DMEM medium and placed in a humidified 
atmosphere incubator at 37°C with 5% CO2. The other four segments were instead 
seeded with 1.2x106/cm2 ucMFB at the twelfth culture passage, covered with DMEM 
medium and placed in a humidified atmosphere incubator at 37°C with 5% CO2. 
Medium was replaced every 2/3 days, in both the experiments. 
 
 
FIG.16 Carotid artery after decellularization (A); 1cm2 segments 
 
Segments were taken at days 7, 14, 21, and processed for histological analysis. 
From the analysis emerged that just few cells remained or penetrate into the tissue, 
instead most of the cells migrated outside the tissue preferring the plastic of the well 
dish, where they adhere.  
Even though the amount of cell on the surface of the tissue was low umbilical cord 
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myofibroblast appeared more prone to interact with the tissue. 
A second experiment was made seeding 1.5x106 cells/cm2 scaffold, using fibrin (Sigma-
Aldrich, St. Louis, USA) as a carrier. The concentration of Fibrinogen (10 mg/mL) and 
Thrombin (10 IU/mL) was in accordance with the standard concentrations used in 
cardiovascular tissue engineering. After static incubation of seeded constructs in 
advanced DMEM supplemented with 10% FBS for seven days, they were processed for 
a preliminary histological analysis, that showed that cells thanks to the fibrin-thrombin 
compound stays on the surface of the decellularized scaffold.  
 
 
9.2 Dynamic cellularizzation 
 
Mammary artery of about 15 cm of length was decellularized with the optimized 
decellularization protocol, maintaining the natural tubular structure, 1.5x106 cells/cm2 
scaffold were seeded inside the tubular scaffold using the Fibrinogen-Thrombin 
compound as carrier and after seeding the construct was placed in humidified 
atmosphere incubator at 37°C with 5% CO2. After four days of static incubation in 
advanced DMEM, the construct was placed into a bioreactor flow system mimicking a 
pulsatile pressure cardiovascular flow environment. The bioreactor consisted in a 
silicone tube with a diameter of 1cm inside which is fixed the tubular graft, this silicone 
tube permit the flow of medium in both internal and external surface (FIG.17).  
 
 
 
FIG.17 The tubular vascular graft seeded with uvMFB placed into the silicone tube (A); whole 
system into the incubator (B). 
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The whole system was placed in a regular humidified incubator at 37°C and 5% CO2 
and air driven by a simple dual-phase control ventilator, which was placed outside the 
incubator and connected to the air chamber of the bioreactor by a single silicone tube. 
The pulsatile flow was slightly increased over the study period and DMEM medium 
was changed every 3/4 days. Construct was harvested after 14 days of biomimetic 
conditioning accordingly (Weber B. et al, 2011). 
 
 
 
 
 
10. EVALUATION OF RE-CELLULARIZATION AND 
MATRICE FORMATION 
 
10.1 Histology 
The tubular graft after fourteen days of dynamic incubation was harvested and 
processed for the paraffin embedding, as previous described. 3µm-thick sections were stained	   with	   haematoxylin	   &	   eosin	   (H&E)	   for the conventional	   histopathological	  analysis,	  according	  to	  the	  histological	  procedures	  and	  observed	  with	  LM. 
 
10.2 Sirius Red Stain 
Collagen is the major insoluble insoluble fibrous protein in the extracellular matrix. 
There are several methods for evaluating tissue fibrosis/collagen deposition, one of this 
is the Sirius Red stain. Sirius Red is a dye that binds to the [Gly-x-y] triple-helix 
structure found in all collagen fibers. (Corinne R. et al, 2011). 3µm-thick paraffin 
embedded sections previously stained with haematoxylin & eosin were brought to 
distilled water and processed for the Sirius Red staining following the manufacturer’s 
instruction. Briefly, after de-waxing and rehydration sections were stained in 0,2% 
picro-sirius red for one hour at rt, washed in water and counterstained with hemalum. 
Sections were washed in water and dehydrated in three changes of 100% ethanol, 
cleared in xylene and mounted in a resinous medium. 
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Sirius Red is studied with a polarization microscopy, it presents different colours in 
regions where collagens I, II and III have been described. Collagen type I appears 
yellow, orange or red while collagen type III appears green. 
 
 
10.3 Pop-off  
 
The Pop-off method allows a precise area in a paraffin-embedded section to be re-
embedded in resin. The area of interest in the stained paraffin-embedded section 
mounted on a glass slide is lightly circled with a diamond pencil on the surface of the 
slide before the coverslip is removed, the circled area should be of the same size of a 
BEEM capsule. The slide is then immersed in xylene to remove the coverslip and then 
rinsed with fresh xylene to ensure removal of the mounting medium. 
When the slide is clean it is immersed in a solution containing xylene and propylene 
oxid in equal part for about two minutes at rt. This immersion is followed by another 
immersion in pure propylene oxid (2min at rt). The slide is then placed in a 2:1 mixture 
of propylene oxid and resin (2min at rt), followed by the placement in a 1:1 mixture of 
propylene oxid and resin (2min at rt) and then transferred in a 1:2 mixture of propylene 
oxid and resin for 10 minutes at rt. A labelled BEEM capsule is placed in a BEEM 
capsule holder (FIG.18). The BEEM capsule is completely filled with resin and placed 
in the holder. The section adhering to the glass slide is inverted over the top of the resin-
filled capsule. The BEEM capsule holder and the slide are placed in a oven at 76°C for 
about 72 hours to carry out the polymerization process. After polymerization and 
cooling at room temperature the glass slide-BEEM unit is removed by pushing the 
capsule up from the underside of the holder. The glass slide is then placed on a 100°C 
hot plate for 15 seconds and after the capsule is cut off. The area of interest remains in 
the resin block and it is processed for the usual TEM analysis. 
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FIG.18 BEEM capsule holder for paraffin section reembedding. Standard capsule well (A); bottom 
of well cutaway (B); resin-filled capsule in cutaway well. The section is inverted over the capsule 
(Bretschneider et al, 1981) 
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11. RESULTS 
 
11.1 Haematoxylin Eosin 
 
In Fig.19, H/E stained sections of a seeded a-cellular scaffold. Samples were harvested 
after 14 days of dynamic culture in a flow-bioreactor. Seeded cells showed a little and 
almost undetectable tissue formation. Cells on the intimal surface appear healthy and in 
specific areas they start migrating into the tissue. 
 
 
FIG. 19 10X magnification HE stained sections. Presence of cells on the intimal  
surface and their progressive migration into the tissue 
 
 
11.2 Sirius Red 
 
Sirius Red is a dye that binds to the [Gly-x-y] triple-helix structure found in all collagen 
fibers. It presents different colours in regions where collagens I, II and III have been 
described. Collagen type I appears yellow, orange or red while collagen type III appears 
green. In figure 20, Sirius Red staining showed layers of immature collagen type III, 
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presumably synthesized from the seeded ucMFBs lying on the intimal surface. 
 
 
 
FIG.20 Sirius Red Staining; In green fibres of collagen type III close to the intimal surface  
 
 
 
11.3 Pop-Off 
 
Pop-off is method that allows a precise area in a paraffin-embedded section to be re-
embedded in resin. Haematoxylin eosin stained sections of cell-free scaffold seeded 
with ucMFBs after the 14th day of dynamic culture in the flow-bioreactor, were 
processed with the Pop-off for the transmission electron microscopy (TEM) anlysis. 
Ultrathin sections were cut with diamond knives using an ultramicrotome, transferred to 
specimen support grids, counterstained with uranyl acetate and lead citrate and observed 
in a Philips 400T trasmission electron microscope. 
In figure 21, ultrastructural analysis revealed 30 nm thick collagen fibres, presumably 
corresponding to the immature collagen. 
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FIG.21 Ultrastructure of 30 nm thick collagen fibres 
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12. DISCUSSION 
 
 
Cardiovascular disease, including coronary artery and peripheral vascular disease, is the 
leading cause of morbidity and mortality in word population, as reported by the World 
Health Organization (WHO). Peripheral vascular disease refers to a cluster of 
conditions in which atherosclerosis, or narrowing of blood vessels, occurs in the 
peripheral circulation, particularly in the legs. Even if, unlike myocardial infarction, has 
a relatively low risk of death PAD causes substantial disability as affected limbs are at 
higher risk of amputation and infection. These statistics demonstrate the growing need 
for the use and development of effective therapies to treat cardiovascular disease. The 
use of autologous vascular substitute like mammary or radial arteries seems to be a 
valid option in PAD treatment. However their use is limited by availability or quality, 
concomitant diseases, previous sampling, and moreover this approach require multiple 
surgical procedures. In the last years for these reasons synthetic xenograft made of 
poly(ethylene terphalates) [Dacron™] and expanded poly(tetrafluoroethylene) [ePTFE 
Teflon™] were successfully used. Good conduits in high-flow low-resistance 
conditions and clinically tested for large diameter (>6 mm) vessels, however almost all 
vascular conduits with a smaller diameter (<6mm) failed for several complications such 
as intimal hyperplasia, atherosclerotic degeneration or thrombosis. To summarize, the 
use of either a synthetic or natural graft has specific individual limitations resulting in a 
high demand for alternative treatments. Decellularization is a promising technique that 
can be utilized to remove cells from a tissue. Several groups have found a multitude of 
uses for the ECM from a decellularized tissue; a hypothetic idea is the in-vivo use of 
decellularized scaffold due to the lack of donors and/or viable tissues. New 
decellularization techniques will continue to develop to become a unique source of 
biologic materials for specific applications. The aim of this thesis is to examine the 
potential use of a decellularized artery as a more physiologically relevant scaffold type, 
when compared to current synthetic polymers. The use of decellularized scaffold 
provides several potential advantages including maintenance of structural integrity 
(mechanical strength and compliance) incorporation of natural binding sites for cells 
and reduction of immune response. The following summarizes the work performed in 
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this thesis to develop and implement the decellularized scaffold. After numerous trials, 
the final decellularization protocol included the successive immersion in 3 solution low-
concentration ionic detergents containing Tris 10 mmol/L; 0.1%; ethylendiamine 
tetraacetic acid (EDTA); 0.1% SDS, Tris 50 mmol/L, NaCl, 0.15 mol/L, 0.1% EDTA, 
being continuously shaken at 37°C in a humidified atmosphere with 5% CO2. 
Decellularization was histological evaluated with Haematoxylin and Eosin dyes to 
visualize eventual nuclei of resisted cells to the process and cellular material, and with 
Thricrome Picro-Mallory and Weigert staining to visualize the extracellular matrix. The 
histological evaluation showed the complete decellularization of artery resulting by the 
lack of hemotoxylin-stained nuclei, obtaining a potential biological-acellular scaffold 
type. Furthermore, histology and ultrastructural microscopy of collagen and elastic 
fibres showed that the ECM structure resisted to the harsh SDS washing remaining 
intact. The second aim of the work was the re-cellularization of cell-free scaffold. For 
this purpose was investigated their capacity to house cells. Myofibroblast-like cells 
isolated from human umbilical cord (ucMFB) and vascular wall-MSC cells  (vwMSCs) 
were tested as potential cells source to re-cellularizate the scaffold. After a static culture 
seeding, ucMFBs showed a higher inclination to adhere, penetrate and populate the cell-
free scaffold. To better mimic a native artery the seeded scaffold was placed in a 
bioreactor. The main advantage in the use of bioreactors in the production on vascular 
tissue engineered graft is that the perfusion system mimics the physiological flow of 
cardiovascular system. The use of bioreactors in tissue engineering field is widely 
increasing because it has been greatly described that they facilitate cell seeding 
procedures on both sides of a 3D tubular matrix; allow seeding and culturing of 
different cell types on either side of the tubular scaffold; enhance oxygenation of the 
culture medium and mass transport, between the medium and the adhering cells; and 
moreover stimulate the cells with hydrodynamic stimuli, favouring the metabolic 
activity and the differentiation process. 
In conclusion, this research provided the documentation to support the potential for a 
decellularized natural human blood vessel to be utilized as a scaffold and it might 
provide a novel approach for generating small-diameter vascular grafts for vascular 
reconstruction surgery. 
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